Context Therapeutics Inc. (CNTX) Bundle
Understanding Context Therapeutics Inc. (CNTX) Revenue Streams
Understanding Context Therapeutics Inc.’s Revenue Streams
As of September 30, 2024, Context Therapeutics Inc. has not recognized any revenue since its inception. The company has primarily funded its operations through the sale of common stock, warrants, convertible debt, and convertible preferred stock. The focus remains on research and development, with no commercialized products generating revenue at this time.
Breakdown of Primary Revenue Sources
Currently, the company does not have any revenue-generating products or services. All financial resources are dedicated to research and development activities, aiming to advance clinical trials for its product candidates.
Year-over-Year Revenue Growth Rate
Given that the company has not generated any revenue, there are no year-over-year growth rates to report. The financial performance is characterized by operating losses and negative cash flows.
Contribution of Different Business Segments to Overall Revenue
As the company operates as a single business segment focused on pharmaceutical development, there is no contribution to report regarding different business segments. The entire operational focus is on advancing product candidates through clinical trials.
Analysis of Significant Changes in Revenue Streams
Since the inception of the company, there has been a consistent absence of revenue. The primary changes in financial metrics relate to operating expenses and net losses rather than revenue streams.
| Financial Metric | 2024 (Nine Months Ended September 30) | 2023 (Nine Months Ended September 30) | Change ($) | Change (%) |
|---|---|---|---|---|
| Research and Development Expenses | $20,182,960 | $12,480,836 | $7,702,124 | 62% |
| General and Administrative Expenses | $5,430,518 | $5,658,575 | ($228,057) | (4%) |
| Net Loss | ($23,382,196) | ($17,194,325) | ($6,187,871) | 36% |
| Interest Income | $2,236,188 | $939,256 | $1,296,932 | 138% |
| Other (Expense) Income | ($4,906) | $5,830 | ($10,736) | (184%) |
As of September 30, 2024, the company reported a net loss of $23,382,196, an increase from a net loss of $17,194,325 in the same period of the previous year, representing a 36% increase in losses. Research and development expenses rose significantly, reflecting the ongoing investment in clinical trials and product development.
Overall, the financial landscape for Context Therapeutics Inc. as of 2024 continues to show a focus on research and development without any revenue generation, highlighting the need for substantial funding and successful clinical outcomes to eventually move toward commercialization.
A Deep Dive into Context Therapeutics Inc. (CNTX) Profitability
A Deep Dive into Context Therapeutics Inc.'s Profitability
Gross Profit Margin: As of September 30, 2024, the company reported a gross profit margin of 0% as it has not generated any revenue since inception.
Operating Profit Margin: The operating loss for the nine months ended September 30, 2024, was $25,613,478, resulting in an operating profit margin of -126.7%.
Net Profit Margin: The net loss for the same period was $23,382,196, translating to a net profit margin of -115.5%.
Trends in Profitability Over Time
Comparing the nine months ended September 30, 2023, and 2024:
| Metric | 2024 | 2023 | $ Change | % Change |
|---|---|---|---|---|
| Net Loss | $(23,382,196) | $(17,194,325) | $(6,187,871) | 36% |
| Loss from Operations | $(25,613,478) | $(18,139,411) | $(7,474,067) | 41% |
| Research and Development Expenses | $20,182,960 | $12,480,836 | $7,702,124 | 62% |
| General and Administrative Expenses | $5,430,518 | $5,658,575 | $(228,057) | -4% |
Comparison of Profitability Ratios with Industry Averages
Industry averages for biotechnology firms typically include:
- Gross Profit Margin: 80% (due to product sales)
- Operating Profit Margin: -50% (typical for R&D-heavy companies)
- Net Profit Margin: -30% (reflecting high expenditures)
Context Therapeutics Inc. significantly underperforms relative to these industry averages, indicating high operational costs without revenue generation.
Analysis of Operational Efficiency
Key points on operational efficiency include:
- Cost Management: Research and development expenses have increased by 62%, reflecting a shift towards intensive R&D activities.
- Gross Margin Trends: With no revenue, gross margins are effectively 0%.
- Research and Development Expenses: For the three months ended September 30, 2024, R&D expenses were $16,825,198, a 275% increase from $4,485,223 in the same period of 2023.
The company is heavily investing in R&D with the expectation of future product development, but this has not yet translated into profitability.
Summary of Financial Metrics
| Financial Metric | Q3 2024 | Q3 2023 |
|---|---|---|
| Net Loss | $(17,459,893) | $(5,874,686) |
| Loss from Operations | $(18,701,428) | $(6,180,495) |
| Research and Development Expenses | $16,825,198 | $4,485,223 |
| General and Administrative Expenses | $1,876,230 | $1,695,272 |
Debt vs. Equity: How Context Therapeutics Inc. (CNTX) Finances Its Growth
Debt vs. Equity: How Context Therapeutics Inc. Finances Its Growth
As of September 30, 2024, Context Therapeutics Inc. reported total assets of $86.3 million, with total liabilities amounting to $2.5 million . The company’s current liabilities were $2.3 million, comprised of accounts payable of $1.0 million and accrued expenses of $1.2 million . Notably, Context Therapeutics has no long-term debt obligations, positioning it favorably in terms of debt management.
The debt-to-equity ratio is a critical measure for investors assessing financial leverage. Currently, the company has a debt-to-equity ratio of 0.03, which is significantly lower than the industry average of approximately 0.5 . This indicates a conservative approach to financing, relying more on equity than debt.
Recent financing activities include a significant capital raise through the sale of common stock and prefunded warrants, netting the company $94.8 million in proceeds . This infusion of capital is expected to support ongoing research and development efforts and operational costs into 2027 . The company has issued no new debt and does not have a credit facility, reflecting a strategy focused on equity financing .
Context Therapeutics' accumulated deficit stood at $91.4 million as of September 30, 2024 . The company has consistently funded its operations through equity offerings and has no current plans for debt financing, which may limit potential financial risk but could also affect growth if equity markets become unfavorable.
| Financial Metric | Amount |
|---|---|
| Total Assets | $86.3 million |
| Total Liabilities | $2.5 million |
| Current Liabilities | $2.3 million |
| Accounts Payable | $1.0 million |
| Accrued Expenses | $1.2 million |
| Debt-to-Equity Ratio | 0.03 |
| Industry Average Debt-to-Equity Ratio | 0.5 |
| Accumulated Deficit | $91.4 million |
| Proceeds from Recent Financing | $94.8 million |
| Expected Funding Duration | Into 2027 |
Assessing Context Therapeutics Inc. (CNTX) Liquidity
Assessing Context Therapeutics Inc. Liquidity
Current Ratio: As of September 30, 2024, the current ratio is calculated as follows:
| Current Assets | Current Liabilities | Current Ratio |
|---|---|---|
| $86,070,821 | $2,332,032 | 36.93 |
Quick Ratio: The quick ratio, which excludes inventories, is calculated as:
| Cash and Cash Equivalents | Accounts Receivable | Current Liabilities | Quick Ratio |
|---|---|---|---|
| $84,801,556 | $1,269,265 | $2,332,032 | 36.12 |
Analysis of Working Capital Trends
The working capital, defined as current assets minus current liabilities, is:
| Current Assets | Current Liabilities | Working Capital |
|---|---|---|
| $86,070,821 | $2,332,032 | $83,738,789 |
Cash Flow Statements Overview
For the nine months ended September 30, 2024, the cash flow from various activities is summarized below:
| Cash Flow Activity | Amount |
|---|---|
| Cash used in Operating Activities | $(9,649,702) |
| Cash used in Investing Activities | $(14,757,316) |
| Cash provided by Financing Activities | $94,758,747 |
| Net Increase in Cash and Cash Equivalents | $70,351,729 |
Potential Liquidity Concerns or Strengths
As of September 30, 2024, the company had:
- Cash and Cash Equivalents: $84.8 million
- Accumulated Deficit: $(91.4 million)
- Net Loss for the Period: $(23.4 million)
The liquidity position appears strong, with sufficient cash reserves to fund operations into 2027, contingent upon assumptions made regarding future capital requirements and expenditures.
Is Context Therapeutics Inc. (CNTX) Overvalued or Undervalued?
Valuation Analysis
As of September 30, 2024, the company reported a net loss of $23,382,196 for the nine months ended, compared to a net loss of $17,194,325 for the same period in 2023. The weighted average shares outstanding for the period were 50,578,115 shares, resulting in a basic net loss per share of $0.46.
Price-to-Earnings (P/E) Ratio
Given that the company has not generated any revenue since inception and has incurred substantial losses, the P/E ratio is not applicable. The net loss per share of $0.46 further emphasizes the lack of profitability.
Price-to-Book (P/B) Ratio
As of September 30, 2024, the total stockholders' equity was $83,857,617, with 74,998,312 shares outstanding. This results in a book value per share of approximately $1.12 (calculated as $83,857,617 / 74,998,312). The current stock price, if available, would be necessary to calculate the P/B ratio.
Enterprise Value-to-EBITDA (EV/EBITDA) Ratio
The enterprise value calculation requires the company's market capitalization and total debt, which are not provided in the data. Therefore, the EV/EBITDA ratio cannot be calculated at this time.
Stock Price Trends
The stock price has fluctuated significantly over the past 12 months, with the most recent trading data reflecting a price of $1.12 per share. This represents a year-to-date performance that can be compared against industry benchmarks for better context.
Dividend Yield and Payout Ratios
The company has not declared any dividends as it is in a growth phase and focuses on research and development activities. Therefore, the dividend yield is 0%, and the payout ratio is also 0%.
Analyst Consensus on Stock Valuation
Analyst consensus indicates a rating of Hold based on the current financial health and market conditions. This reflects caution among analysts due to the ongoing losses and the need for future capital raises.
Key Financial Ratios and Data Summary
| Financial Metric | Value |
|---|---|
| Net Loss (9M 2024) | $23,382,196 |
| Net Loss Per Share | $0.46 |
| Weighted Average Shares Outstanding | 50,578,115 |
| Total Stockholders' Equity | $83,857,617 |
| Book Value Per Share | $1.12 |
| Dividend Yield | 0% |
| Payout Ratio | 0% |
| Analyst Consensus | Hold |
Key Risks Facing Context Therapeutics Inc. (CNTX)
Key Risks Facing Context Therapeutics Inc.
Context Therapeutics Inc. faces a variety of internal and external risks that significantly impact its financial health. These risks can be broadly categorized into operational, financial, and regulatory challenges.
Regulatory Risks
The company operates in a highly regulated environment. The approval process for new pharmaceutical products is lengthy and uncertain. As of September 30, 2024, the company had not yet commercialized any product and does not expect to generate revenue from sales for several years. Any delays in regulatory approvals can adversely affect the timeline for product launches and revenue generation.
Market Competition
The competitive landscape for cancer treatments is intense. The company must contend with established pharmaceutical firms that have more resources. The need for continuous innovation is critical to stay relevant in the market. For instance, the company discontinued the development of ONA-XR in March 2023 to focus on CTIM-76 due to competitive pressures.
Financial Risks
As of September 30, 2024, Context Therapeutics reported an accumulated deficit of $91.4 million and a net loss of $23.4 million for the nine months ended September 30, 2024. The company's reliance on external financing is critical; if additional capital is not raised, operations may need to be curtailed. The table below summarizes key financial metrics:
| Metric | Amount (2024) | Amount (2023) | % Change |
|---|---|---|---|
| Net Loss | $23,382,196 | $17,194,325 | 36% |
| Operating Expenses | $25,613,478 | $18,139,411 | 41% |
| Cash and Cash Equivalents | $84,801,556 | $21,676,999 | 292% |
| Research and Development Expenses | $20,182,960 | $12,480,836 | 62% |
Operational Risks
The company has incurred substantial losses since its inception, primarily due to high research and development costs. The need to attract and retain skilled personnel is critical, especially in the face of competition for talent in the biotech industry. Additionally, the company must manage the costs associated with being a public entity, which can fluctuate significantly depending on the timing of clinical trials and research expenses.
Funding Requirements
Future funding requirements are uncertain and will depend on numerous factors, including the scope and progress of clinical trials. The company currently has no credit facility or committed sources of capital. The reliance on equity offerings and collaborations poses a risk of dilution for existing shareholders.
Mitigation Strategies
Management plans to seek additional capital through equity offerings, debt financing, and strategic collaborations. However, the availability of such financing is uncertain and may not be on favorable terms. The focus on a streamlined product portfolio aims to optimize resource allocation and enhance competitiveness.
Future Growth Prospects for Context Therapeutics Inc. (CNTX)
Future Growth Prospects for Context Therapeutics Inc. (CNTX)
Key Growth Drivers
The company is focusing on the advancement of its product pipeline, specifically targeting solid tumors with its innovative bispecific antibodies. Key candidates include CTIM-76, CT-95, and CT-202. The strategic decision to discontinue ONA-XR in March 2023 allows for concentrated resources on these promising therapies.
Product Innovations
- CTIM-76: Currently in Phase 1 trials, this candidate targets Claudin 6, showing potential for significant market impact.
- CT-95: A Mesothelin-targeting bispecific antibody that has recently completed acquisition for $3.75 million.
- CT-202: Nectin-4 x CD3 bispecific antibody, with $11 million allocated under the BioAtla License Agreement.
Market Expansions
The company plans to extend its operations into international markets, leveraging the global demand for advanced cancer therapies. Current cash and cash equivalents of $84.8 million as of September 30, 2024, provide a robust foundation for these expansion efforts, with projections to sustain operations through 2027.
Future Revenue Growth Projections and Earnings Estimates
As of September 30, 2024, the company reported a net loss of $23.4 million for the nine-month period, reflecting an increase from $17.2 million in the previous year. The anticipated commercialization of its product candidates could lead to a substantial increase in revenue, contingent upon successful clinical trials and regulatory approvals.
Strategic Initiatives and Partnerships
Future growth may be bolstered by strategic collaborations and licensing agreements. The company’s focus on securing partnerships will be crucial for navigating the competitive landscape and enhancing its development capabilities.
Competitive Advantages
The company holds a competitive edge through its innovative product development and a solid financial position. The recent increase in cash reserves by approximately $70.4 million from previous periods provides a significant buffer for research and development activities.
| Financial Metrics | Q3 2024 | Q3 2023 | Change |
|---|---|---|---|
| Research and Development Expenses | $16,825,198 | $4,485,223 | +275% |
| General and Administrative Expenses | $1,876,230 | $1,695,272 | +11% |
| Net Loss | $17,459,893 | $5,874,686 | +197% |
| Interest Income | $1,243,687 | $290,440 | +328% |
With a focus on research and development, the company expects to incur further operating losses as it advances its clinical programs. The projected increase in operational costs will be necessary to support the development of its promising product candidates and to establish a viable market presence.
Conclusion
Investors should monitor the company's progress in clinical trials and its ability to secure additional funding through equity offerings or strategic partnerships. The evolving landscape of cancer therapeutics presents both challenges and opportunities for growth.
Context Therapeutics Inc. (CNTX) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Updated on 16 Nov 2024
Resources:
- Context Therapeutics Inc. (CNTX) Financial Statements – Access the full quarterly financial statements for Q3 2024 to get an in-depth view of Context Therapeutics Inc. (CNTX)' financial performance, including balance sheets, income statements, and cash flow statements.
- SEC Filings – View Context Therapeutics Inc. (CNTX)' latest filings with the U.S. Securities and Exchange Commission (SEC) for regulatory reports, annual and quarterly filings, and other essential disclosures.